Showing results (1-10 of 279) with videos related to

Sort By:
Pageof 28
The Journal of Clinical Investigation|February 1, 1971
Studies of a hypomorphic variant of human C3C A Alper, F S Rosen
The Journal of Experimental Medicine|March 1, 1973
Serum-dependent phagocytosis of paraffin oil emulsified with bacterial lipopolysaccharideT P Stossel, C A Alper, F S Rosen
Proceedings of the National Academy of Sciences of the United States of America|October 1, 1972
Inactivator of the third component of complement as an inhibitor in the properdin pathwayC A Alper, F S Rosen, P J Lachmann
The Journal of Allergy and Clinical Immunology|February 1, 1986
The metabolism of C1 inhibitor and C1q in patients with acquired C1-inhibitor deficiencyJ Melamed, C A Alper, M Cicardi, et al.
The Journal of Clinical Investigation|April 1, 1983
Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edemaM Quastel, R Harrison, M Cicardi, et al.
Science (New York, N.Y.)|August 6, 1971
C1 inhibitor: evidence for decreased hepatic synthesis in hereditary angioneurotic edemaA M Johnson, C A Alper, F S Rosen, et al.
Clinical Immunology and Immunopathology|January 1, 1983
Attachment of [35S]cysteine to the labile site of the third component of complement via the alternative pathwayC J Rutherford, C A Alper, F S Rosen, et al.
The Journal of Clinical Investigation|November 1, 1970
Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infectionC A Alper, N Abramson, R B Johnston, et al.
The Journal of Clinical Investigation|October 1, 1971
Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edemaF S Rosen, C A Alper, J Pensky, et al.
The Journal of Clinical Investigation|September 1, 1975
Metabolism of properdin in normal subjects and patients with renal diseaseJ B Ziegler, F S Rosen, C A Alper, et al.
Pageof 28